

MMWR™

MORBIDITY AND MORTALITY WEEKLY REPORT

- 889 Gonorrhea Among Men Who Have Sex with Men — Selected Sexually Transmitted Diseases Clinics, 1993–1996
- 893 Progress Toward Global Measles Control and Elimination, 1990–1996
- 897 Chronic Interstitial Lung Disease in Nylon Flocking Industry Workers — Rhode Island, 1992–1996
- 901 National Fire Prevention Week — October 5–11, 1997
- 903 AIDS Rates


Gonorrhea Among Men Who Have Sex with Men — Selected Sexually Transmitted Diseases Clinics, 1993–1996

Among men who have sex with men (MSM), gonorrhea trends may reflect changes in sexual behaviors that also influence risk for human immunodeficiency virus (HIV) infection (1). Data from the Gonococcal Isolate Surveillance Project (GISP) were used to assess trends in gonococcal infection (GC) among MSM. For the subset of GISP sites where a substantial proportion of GC cases were in MSM, a special survey of the local areas was conducted to describe factors associated with GC in MSM. This report summarizes the results of that survey, which indicate that the number and proportion of MSM diagnosed with GC has increased in the sexually transmitted diseases (STD) clinics of several large cities in the United States.

GISP is a sentinel surveillance project begun in 1987 to monitor antimicrobial resistance in *Neisseria gonorrhoeae*. Through GISP, STD clinics in 26 U.S. cities collect gonococcal isolates and clinical information, including sexual orientation, from the first 20 male patients with urethral GC examined each month. The sexual orientation of GISP participants examined from 1993 through 1996 was analyzed, and surveys were conducted of the clinics where >5% of GISP isolates over the 4-year period were from MSM (n=8)*. The survey collected information from locally available data about absolute numbers of GC cases in MSM, in contrast to the proportions that were available from GISP data. The survey also addressed overall gonorrhea and other STD (i.e., nongonococcal urethritis [NGU]) trends and factors that could be associated with GC trends in MSM (i.e., changes in clinic practices, geographic clustering of cases, sexual risk behaviors, illicit drug use, and HIV serostatus).

MSM comprised 5.0% of all cases in the GISP sample in 1993, a proportion similar to preceding years, and 8.7% in 1996 (p<0.001). Among the subset of eight GISP clinics where >5% of isolates were obtained from MSM, the proportion increased from 12.0% (range: 4.2%–35.1%) in 1993 to 23.5% (range: 7.2%–57.1%) in 1996 (p<0.001) (Figure 1). The median age of MSM reported from all 26 clinics was 30 years and remained stable from 1993 through 1996. Changes in the race/ethnicity distribution were not statistically significant: from 1993 to 1996, the percentage of MSM who were

*Clinics were located in Denver; Honolulu; Long Beach, Orange County, San Diego, and San Francisco, California; Portland, Oregon; and Seattle, Washington.

*Gonorrhea — Continued***FIGURE 1. Percentage of *Neisseria gonorrhoeae* isolates obtained from men who have sex with men — sexually transmitted diseases clinics in eight cities, 1993–1996**

Source: Gonococcal Isolate Surveillance Project

white increased from 58.6% to 64.9%, and the percentage who were black decreased from 23.0% to 17.4%.

Clinics in San Francisco; Seattle; and Portland, Oregon, experienced increases in both the absolute number and proportion of gonorrhea cases among MSM. From 1994 to 1996, GC among MSM at the Seattle clinic increased 125% (from 51 cases to 115 cases), while clinic visits by MSM increased by 17%. During the same period, the proportion of positive rectal and pharyngeal GC cultures among MSM at the Seattle clinic increased from 5.0% to 8.0% and from 1.5% to 6.7%, respectively. From 1994 to 1995 at the San Francisco clinic, the absolute number of MSM with GC increased 24% (from 271 to 336); similar increases occurred in the number of GC cases identified from a neighborhood known to have a high concentration of MSM and in the number of rectal GC cases. From 1995 to 1996 at the Portland clinic, the number of MSM with GC increased 124% (from 33 cases to 74 cases). Clinic visits by MSM during the same period increased, but the number of MSM seen by the clinic decreased, indicating that the increase in GC cases did not result from an increase in the number of MSM served by the clinic.

Enhanced GC screening efforts targeted to MSM were initiated in San Francisco in early 1996, potentially contributing to an increase in reported cases in 1996; however, the absolute number of cases of GC in 1996 were not available at the time of this report. Changes in screening or outreach to MSM were not identified at other clinics in this survey. In addition, none of the clinics surveyed were aware of any changes in

Gonorrhea — Continued

the availability of clinical services that might have prompted MSM to shift STD care-seeking from other venues to public STD clinics.

From 1994 to 1996, NGU increased 27% among MSM at the Seattle clinic and 40% among MSM at the San Francisco clinic from 1993 to 1995. Approximately one fourth of MSM with GC identified at the Seattle and Portland clinics and one fourth of all MSM examined at the San Francisco clinic were HIV positive.

Of the remaining five clinics surveyed, those in Honolulu and San Diego reported substantial increases in the number of MSM with GC. In San Diego, from 1996 to the first quarter of 1997, the proportion of rectal specimens that were positive for *N. gonorrhoeae* increased from 3.9% (seven of 180) to 14.6% (six of 41), and the proportion of male pharyngeal cultures that were positive increased from 2.9% (15 of 522) to 4.0% (five of 125). Based on five interviews of MSM with GC, four also were HIV infected. At the Denver clinic, the absolute number of MSM with GC decreased despite an increase in the proportion of GC cases identified in MSM from 1995 to 1996. In comparison with other clinics surveyed, the Denver clinic observed an increase in the number of black MSM examined from 1995 to 1996. The Long Beach and Orange County, California, clinics are investigating local trends in GC among MSM.

Reported by: W Whittington, Univ of Washington; S Desmon, Seattle-King County Dept of Public Health, Seattle. C Kent, R Kohn, San Francisco Dept of Public Health, San Francisco; T Brazell, MD, San Diego Dept of Health Svcs, San Diego; JM Montes, STD Control Br, California Dept of Health Svcs. D Harger, V Fox, Oregon Health Div. R Ohye, Hawaii Dept of Health. FN Judson, MD, Denver Dept of Health, Denver. Gonorrhea, Chlamydia, and Chancroid Br, Div of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases; Epidemiology and Surveillance Br, Div of STD Prevention, National Center for HIV, STD, and TB Prevention, CDC.

Editorial Note: The incidence of gonorrhea among MSM declined substantially in the United States during the early 1980s (2) as the HIV epidemic led to substantial reductions in sexual risk behaviors (3). However, findings in both the United States and Europe indicate a possible reversal in GC trends among MSM (4,5). Several studies have documented relapses in high-risk behavior among MSM, including unprotected anogenital intercourse (1,6). A recent multicity survey of MSM aged 15–22 years indicated that HIV was highly prevalent (5%–10%) in this population, coincident with a high rate of unprotected anal sex (7).

The findings in this report indicate that, despite a continuing decline in overall rates of GC in the United States (8), the incidence of GC in MSM may be increasing in several U.S. cities. This increase cannot be explained by such factors as improved case ascertainment or increased screening in this population. This report also documented increases in rectal GC in several clinics, an indicator of unprotected anal intercourse. Although complete data were unavailable, preliminary observations from Portland, San Francisco, and Seattle linked GC cases in MSM with attendance at certain local clubs and other places frequented by MSM. Observations from Seattle further implicated sexual activities with anonymous partners and the use of illicit drugs and alcohol in the increase in GC cases among MSM.

An increase in high-risk encounters among MSM could explain the increase in GC cases and could enhance HIV transmission in this population. Among clinics with information about HIV status, approximately one fourth of MSM with GC also were HIV infected. The presence of urethritis in persons with HIV increases the quantity of HIV in their semen (9) and presumably the likelihood of HIV transmission, while the pres-

Gonorrhea — Continued

ence of urethritis in persons without HIV has been associated with an increased likelihood of HIV acquisition (10).

Because information about sexual orientation and behaviors is not part of routine GC case reporting, data about GC trends among MSM must be obtained through special surveillance efforts. This report demonstrates how a sentinel surveillance system designed for tracking antimicrobial resistance can be useful for following epidemiologic trends. However, proportional changes noted in GISP data may require further investigation using local data.

STD clinics and other facilities that serve substantial numbers of MSM are encouraged to collect and analyze local data to follow trends in STDs and sexual behaviors that may increase the risk for acquisition or transmission of HIV infection among MSM. The increase in GC among MSM underscores the need for innovative approaches to achieving and maintaining safer-sex practices among MSM. In addition, the relation between GC and the spread of HIV (9,10) necessitates specific attention to GC control, including routine screening for GC among MSM served by both public and private providers, prompt treatment of infection, and appropriate partner management. Public health agencies and other organizations serving MSM must recognize the importance of GC as a public health problem that is linked, through behavior and biology, to spread of HIV.

References

1. de Wit JB, van de Hoek JA, Sandfort TG, van Griensven GJ. Increase in unprotected anogenital intercourse among homosexual men. *Am J Public Health* 1993;83:1451-3.
2. Handsfield HH. Decreasing incidence of gonorrhea in homosexually active men—minimal effect on risk of AIDS. *West J Med* 1985;143:469-70.
3. Becker MH, Joseph JG. AIDS and behavioral change to reduce risk: a review. *Am J Public Health* 1988;78:394-410.
4. Handsfield HH, Schwebke J. Trends in sexually transmitted diseases in homosexually active men in King County, Washington, 1980-1990. *Sex Transm Dis* 1990;17:211-5.
5. van den Hoek JA, van Griensven GJ, Coutinho RA. Increase in unsafe homosexual behaviour [Letter]. *Lancet* 1990;336:179-80.
6. Stall R, Ekstrand M, Pollack L, McKusick L, Coates TJ. Relapse from safer sex: the next challenge for AIDS prevention efforts. *J Acquir Immune Defic Syndr* 1990;3:1181-7.
7. Valleroy LA, MacKellar D, Jacobs T. HIV and risk behaviour prevalence among young men who have sex with men sampled in six urban counties in the U.S.A. [Abstract Tu.C.2407]. Presented at the XI International Conference on AIDS. Vancouver, 1996.
8. Division of STD Prevention, National Center for HIV, STD, and TB Prevention. Sexually transmitted disease surveillance, 1995. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, CDC, September 1996.
9. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. *Lancet* 1997;349:1868-73.
10. Deschamps MM, Pape JW, Hafner A, Johnson WD Jr. Heterosexual transmission of HIV in Haiti. *Ann Intern Med* 1996;125:324-30.

Progress Toward Global Measles Control and Elimination, 1990–1996

In 1989, the World Health Assembly resolved to reduce measles morbidity by 90% and measles mortality by 95% by 1995, compared with disease burden during the prevaccine era (1). By 1996, the estimated incidence and death rates for measles worldwide were reduced by 78% and 88%, respectively (2). In 1990, the World Summit for Children adopted a goal of vaccinating 90% of children against measles by 2000. However, routine measles vaccination coverage has remained relatively stable since 1990, and an estimated 1 million children continue to die from this preventable disease each year. During the 1990s, the widespread use of innovative measles-control strategies in the Region of the Americas and countries such as Mongolia, South Africa, and the United Kingdom demonstrated that high-level measles control and even interruption of transmission is feasible over large geographic areas. This report updates the status of measles control and elimination worldwide and includes disease surveillance and vaccination coverage data received by the World Health Organization (WHO) headquarters in Geneva, Switzerland, as of August 29, 1997. These findings indicate that, in some regions, substantial progress has been made to control and interrupt measles transmission; in others, measles continues to cause high morbidity and mortality because of failure to implement measles-control strategies.

STAGES OF MEASLES CONTROL

Based on implementation of a combination of vaccination and surveillance strategies, countries are considered to be in one of three stages: control*, outbreak prevention, or elimination†.

Measles Control

In the control stage, the objective is to achieve high routine coverage with one dose of measles vaccine among infants to reduce measles morbidity and mortality. To accelerate measles control in large urban and other high-risk areas with a substantial proportion of a country's unvaccinated children and measles deaths, mass vaccination campaigns targeting children aged 9 months to 3–5 years have been recommended (3).

Measles Outbreak Prevention

Since the mid-1990s, an increasing number of countries where measles incidence has been persistently reduced have adopted aggressive vaccination strategies to prevent forecasted measles outbreaks or interrupt transmission completely. Administration of supplemental doses of measles vaccine through mass vaccination campaigns has resulted in high levels of population immunity and has interrupted transmission. In some countries, after the initial mass campaign, an additional dose of measles vaccine is recommended at school entry.

Measles Elimination

In the Region of the Americas, the Pan American Sanitary Conference resolved in 1994 to eliminate measles from the Western Hemisphere by 2000 (4) using the following strategies: 1) conducting a one-time "catch-up" vaccination campaign targeting all

*Reduction of disease incidence and/or prevalence to an acceptable level as a result of deliberate efforts, requiring continued control measures.

†Reduction of the incidence of a disease to zero as a result of deliberate efforts, requiring continued control measures.

Global Measles Control and Elimination — Continued

children aged 9 months–14 years; 2) achieving and maintaining high routine measles vaccination coverage among children aged 12–23 months; 3) conducting periodic “follow-up” campaigns targeting all children aged 1–4 years; and 4) conducting enhanced surveillance with laboratory investigation of suspected cases (4). Other regions and countries have implemented or are considering implementation of strategies aimed at interrupting measles virus transmission.

PROGRESS TOWARD IMPLEMENTING STRATEGIES**Routine Vaccination Coverage**

From 1977 (when the Expanded Program on Immunization began monitoring coverage) to 1990, global reported coverage with one dose of measles vaccine administered through routine services increased from approximately 5% in 1977 to 16% in 1983 and to 76% in 1990. Since 1990, routine measles vaccination coverage has remained relatively stable (Table 1), with reported coverage at 81% in 1996 (Figure 1). Comparing 1990 and 1996 data, reported routine vaccination coverage increased 3%–11% in the six WHO regions. In 1996, a total of 73 countries achieved coverage of >90%. Nineteen countries reported coverage of <50%; of these, 16 were in Africa. To achieve global coverage of 90%, at least 14.3 million additional children need to be vaccinated each year, nearly 60% of whom reside in seven countries (Brazil, China, Ethiopia, India, Kenya, Nigeria, and Pakistan).

Urban Vaccination Campaigns

During 1993–1996, several countries in Asia (Bangladesh, India, Myanmar, Nepal, and the Philippines) conducted urban vaccination campaigns targeting high-risk areas to reduce measles morbidity and mortality. However, surveillance data are insufficient to accurately assess the impact of these campaigns.

Outbreak Prevention or Elimination Campaigns

During 1990–1996, a total of 49 countries conducted a catch-up vaccination campaign to interrupt measles transmission, administering measles vaccine to approximately 166 million children aged <18 years (93% of the population targeted). Approximately 142 million of these doses were administered in the Americas. In addition, 29 countries in the Americas conducted at least one follow-up campaign.


TABLE 1. Reported number of measles cases and reported measles vaccination coverage, by World Health Organization (WHO) region, 1990 and 1996*

Region	No. cases			Vaccination coverage		
	1990	1996	% Change from 1990 to 1996	1990	1996	% Point change from 1990 to 1996
African	481,294	445,949	– 7%	53	56	3%
American	246,607	2,109	–99%	77	85	8%
Eastern Mediterranean	59,502	20,361	–66%	76	85	9%
European	188,306	162,967	–13%	80	86	6%
Southeast Asian	225,144	81,477	–64%	71	82	11%
Western Pacific	156,139	84,459	–46%	93	96	3%
Total	1,356,992	797,322	–41%	76	81	5%

*As reported to the WHO headquarters in Geneva, Switzerland, by August 29, 1997.

Global Measles Control and Elimination — Continued

FIGURE 1. Reported number of measles cases and reported measles vaccination coverage — worldwide, 1983–1996*



*As reported to the World Health Organization headquarters in Geneva, Switzerland, by August 29, 1997.

Measles Surveillance

Establishment of measles surveillance remains a major challenge in both industrialized and developing countries. For example, measles is not a notifiable disease in Austria, France, Germany, and Japan. Even in countries where measles is notifiable, there is substantial underreporting of cases, and information about age and vaccination status of cases often is not collected.

In the Region of the Americas, measles surveillance has been strengthened substantially since 1990. A total of 43 (91%) countries have reported weekly to the regional office, and standardized case-based reporting of measles cases, including laboratory confirmation, has been established.

The reliability of clinical diagnosis of measles declines as the incidence of the disease decreases to very low levels. The current laboratory-confirmation strategy is based on a measles-specific immunoglobulin M (IgM) enzyme immunoassay (EIA) at national laboratories with confirmatory testing by IgM capture EIA at reference laboratories. In addition, a measles virus reference data bank is being established (5). Eight genotypes of measles virus have been identified worldwide. Additional measles isolates are needed to compile a global genotype map to facilitate tracking of virus transmission worldwide.

*Global Measles Control and Elimination — Continued***IMPACT OF STRATEGY IMPLEMENTATION ON MEASLES INCIDENCE**

During 1980–1996, the number of reported measles cases worldwide declined from 4.4 million in 1980 to 1.3 million in 1990 and to approximately 0.8 million in 1996. However, measles reporting is incomplete; the actual burden from measles in 1996 is an estimated 36.5 million cases and 1 million deaths (6). A total of 40 countries (representing 1% of the global population) reported zero measles cases in 1996, compared with 12 countries in 1990. These 40 countries primarily are small island nations in the Region of the Americas (23), the Western Pacific Region (nine), and the African Region (four).

In 1996, most (445,949 [62%]) of the measles cases worldwide were reported from the African Region (Table 1). Of the six WHO regions, disease burden in 1996 was lowest in the Americas (2109 cases); 488 (23%) cases were reported from the United States. This represented a 99% decline in number of cases in the region compared with 1990 and the lowest number ever reported by this region.

Reported by: Expanded Program on Immunization, Global Program for Vaccines and Immunization, World Health Organization, Geneva, Switzerland. Respiratory and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases; Measles Activity, Epidemiology and Surveillance Div; Polio Eradication Activity, National Immunization Program, CDC.

Editorial Note: Despite the widespread availability of safe and effective measles vaccines since 1963, measles still accounts for 10% of global mortality from all causes among children aged <5 years (6); it is the eighth leading cause of death worldwide, representing 2.7% of disability-adjusted life-years in 1990 (6). Failure to deliver at least one dose of measles vaccine to all infants continues to be the primary reason for this preventable morbidity and mortality.

As a result of ongoing progress toward global poliomyelitis eradication[§], increasing attention has been focused on improving measles control worldwide. In the Region of the Americas, the combination of conducting catch-up and follow-up vaccination campaigns and increasing routine vaccination coverage has demonstrated that measles transmission can be interrupted over large geographic areas (4). Although measles eradication is technically feasible (7), several programmatic, political, and financial obstacles must be overcome before such an eradication goal could be achieved. Polio eradication has stimulated acceleration of measles control worldwide and, in the European Region and the Eastern Mediterranean Region of WHO, has resulted in efforts to establish regional measles-elimination goals. Evaluation of elimination strategies in these regions and countries will provide valuable information for developing a global measles-eradication strategy.

Three immediate measures are necessary to attain disease-reduction and coverage goals and to decrease the number of deaths attributable to measles. First, countries should increase coverage with at least one dose of measles vaccine among infants, especially in countries in Sub-Saharan Africa, where a substantial number of measles deaths continue to occur each year. Second, more aggressive measles vaccination efforts are needed, including the use of mass campaigns in large urban and other high-risk areas (8). However, experience from countries such as Philippines (9) indicates that unvaccinated children frequently are missed by these campaigns unless

[§]Permanent reduction of the worldwide incidence of a disease to zero as a result of deliberate efforts, obviating the need for further control measures.

Global Measles Control and Elimination — Continued

special efforts are made to accurately identify the areas unreached by routine vaccination services. This experience emphasizes the need to develop the infrastructure necessary to provide routine vaccination services to these hard-to-reach communities. Third, surveillance must be strengthened as a critical component of accelerated measles control. Improved surveillance is necessary to evaluate the impact of strategies and to monitor the prevalence of susceptible persons in a population. When countries progress from measles-control to measles-elimination activities, surveillance must be sufficiently sensitive to rapidly detect importations of virus. As measles control accelerates and measles-elimination efforts are implemented, the diagnosis of measles will increasingly rely on laboratory confirmation. The establishment of a global measles laboratory network is essential for countries in the outbreak-prevention or measles-elimination stage.

Activities are ongoing to better estimate the global disease burden of measles, the cost and effectiveness of different control and elimination strategies, the interaction between measles elimination and polio eradication, and the benefits of measles eradication for development of health systems. However, these activities should not delay more immediate efforts to reduce the substantial disease burden caused by measles.

References

1. World Health Assembly. Executive summary. Geneva, Switzerland: World Health Organization, 1989; resolution no. WHA 42.32.
2. Global Program for Vaccines and Immunization. Progress toward 1995 measles control goals and implications for the future. Geneva, Switzerland: World Health Organization, 1996; publication no. WHO/GPV/SAGE 96.04.
3. Aylward BR, Clements J, Olive JM. The impact of immunization control activities on measles outbreaks in middle and low income countries. *Intern J Epidemiol* 1997;26:662–9.
4. de Quadros CA, Olive JM, Hersh BS, et al. Measles elimination in the Americas: evolving strategies. *JAMA* 1996;275:224–9.
5. Rota JS, Heath JL, Rota PA, et al. Molecular epidemiology of measles virus: identification of pathways of transmission and implications for measles elimination. *J Infect Dis* 1996;173:32–7.
6. Christopher JL, Lopez AD, ed. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020—summary. Geneva, Switzerland: World Health Organization, 1996:17–26.
7. CDC. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. *MMWR* 1997;46(no. RR-11).
8. Anonymous. Expanded programme on immunization—accelerated measles strategies. *Wkly Epidemiol Rec* 1994;69:229–34.
9. Tangermann RH, Costales M, Flavier J. Poliomyelitis eradication and its impact on primary health care in the Philippines. *J Infect Dis* 1997;175(suppl 1):S272–S276.

Chronic Interstitial Lung Disease in Nylon Flocking Industry Workers — Rhode Island, 1992–1996

Interstitial lung disease (ILD) occurs infrequently; some cases are attributed to sarcoidosis, pulmonary hemorrhage syndromes, connective tissue diseases, hypersensitivity pneumonitis, drugs, radiation, and mineral dusts (e.g., silica or asbestos). However, most cases of ILD are of uncertain classification or etiology (1). This report describes preliminary findings of the investigation in Rhode Island of an outbreak of ILD among workers involved in the manufacture of finely cut nylon (flock) and flocked

Interstitial Lung Disease — Continued

fabric (used for upholstery, clothing, and automobiles); the findings provide evidence of a newly recognized occupational illness.

Description of Index Cases

In November 1994, a 35-year-old textile worker was referred to a university-based occupational health clinic for evaluation of chronic ILD. No workplace exposures were initially identified as causing his illness, and during the following 12 months, he recovered almost completely while remaining out of work and receiving systemic corticosteroids. In January 1996, a 28-year-old man was referred to the clinic for evaluation of biopsy-confirmed ILD, characterized by bronchiolocentric nodular and diffuse interstitial lymphoid infiltrates and mild interstitial fibrosis that met histologic criteria for nonspecific interstitial pneumonia (NSIP) (2). Both men worked at the same nylon flocking plant in Rhode Island; further inquiry revealed that at the company's plant in Canada, five cases of ILD had been diagnosed during 1990–1991 (3), and two cases had been diagnosed in 1995. In March 1996, at the request of the company and with the cooperation of the workers' union, investigations were undertaken by the Brown University Program in Occupational Medicine and CDC's National Institute for Occupational Safety and Health (NIOSH).

Medical/Epidemiologic Investigation

To identify additional ILD cases among current production workers (n=127) at the Rhode Island plant, all employees with persistent respiratory symptoms were encouraged to undergo full pulmonary function testing, chest radiography, and high resolution computerized chest tomography (HRCT). Those with unexplained restrictive lung function, impaired diffusing capacity, or HRCT findings consistent with ILD were referred for transbronchial or wedge biopsy. A single pulmonary pathologist reviewed all specimens as well as those of the five case-patients in Canada who had biopsies. A case of "flock-worker's lung" was defined as 1) a histologic diagnosis of NSIP (2) characterized by bronchiolocentric nodular and diffuse interstitial lymphoid infiltrates and nonuniform alveolar filling by macrophages, with or without interstitial fibrosis; 2) other histologic manifestations of ILD not attributable to another disease; or 3) in the absence of a tissue specimen, a grossly abnormal distribution of cell types on bronchoalveolar lavage (BAL) with restrictive lung function and HRCT findings of either diffuse ground glass opacity or micronodularity.

The study cohort included all current and former production workers employed at the Rhode Island facility on or after June 15, 1990, and who had worked for ≥ 18 months before September 15, 1996 (n=165).^{*} After working 18 months, cohort members contributed person-years at risk for time subsequently worked from June 15, 1990, through September 15, 1996. General population estimates for age- and sex-specific incidence of pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF) and for sex-specific incidence of all ILD were obtained from an ILD registry for Bernalillo County, New Mexico (1)[†]; using these estimates and weights based on the demo-

^{*}The company's recordkeeping system precluded formation of a larger cohort and necessitated the 18-month employment requirement.

[†]These data from Bernalillo County represent the only available estimates of background incidence of ILD cases. For the category of "all ILD," only sex-specific rates are available.

Interstitial Lung Disease — Continued

graphics of the study cohort, standardized incidence ratios for PF/IPF[§] and for all ILD were calculated. Ninety-five percent confidence intervals (CIs) for these estimates were derived by exact Poisson calculations.

Among the 165 members of the cohort, seven (4%) were identified with “flock-worker’s lung.” The mean age for these seven was 41 years (range: 28–57 years); six were men. Two were current smokers, four had discontinued smoking ≥ 18 months before diagnosis, and one had never smoked. ILD had been diagnosed in these persons in 1992 (one), October 1994 (one), December 1995 (one), and April–September 1996 (four). The median latencies from time of hire to onset of symptoms (gradually progressive dry cough and dyspnea) and from onset of symptoms to time of diagnosis were 6 years (range: 9 months–31 years) and 1 year (range: 4 months–4 years), respectively. Two workers reported worsening symptoms while at work, but no job category or department was associated with illness. Serologic test results (rheumatoid factor, antinuclear antibody, and hypersensitivity pneumonitis precipitins) were normal except for nondiagnostic findings in two workers. Case-patients experienced symptomatic, radiographic, and functional improvement within weeks to months of leaving work; two received corticosteroids, one remained dependent on supplemental oxygen for an additional 3 years, and none have recovered completely.

Tissue obtained from transbronchial (n=2) and wedge (n=4) biopsies demonstrated NSIP in five patients and bronchiolitis obliterans organizing pneumonia (BOOP) in the sixth. All six had nodular lymphoid infiltrates; four had germinal centers. The seventh case was diagnosed based on a BAL finding of 40% eosinophils, moderate restrictive lung function, and grossly abnormal HRCT. All of the biopsies from the five case-patients in Canada revealed NSIP; two also showed dominant areas of diffuse alveolar damage, and three revealed lymphoid nodules with germinal centers. No granulomas (suggesting hypersensitivity pneumonitis) or birefringent particles (suggesting certain pneumoconioses) were observed in any of the histologic specimens.

At the Rhode Island plant, the crude incidences of “flock-worker’s lung” and of all ILD (including two cases of talcosis and one case of pulmonary histiocytosis X) were 10.5 cases per 1000 person-years and 15 cases per 1000 person-years, respectively. The standardized incidence ratios for PF/IPF and for all ILD were 258 (95% CI=104–530) and 48 (95% CI=23–88), respectively.

Environmental Investigation

In flock manufacture, nylon thread previously impregnated with a titanium dioxide delusterant is dyed, coated (with a finish consisting of tannic acid, an ammonium ether of potato starch, and fatty alcohol derivatives), cut, dried, and bagged. Flocked fabric is made by using the flock’s electrostatic charge to place the flock on acrylic adhesive-covered cotton-polyester fabric, which is then heat-cured. Exposures generic to the industry include bioaerosols, nylon fiber $\geq 12 \mu$ in diameter, a finishing agent, acrylic adhesive, nonfibrous zeolite, heat transfer oil, and thermal degradation products. Preliminary air sampling at the Rhode Island plant, collected volumetrically, revealed extremely high short-term total dust concentrations (up to 83 mg/m³), only modest concentrations of fungal spores and endotoxin, low levels of volatile organic

[§]Background rates of PF/IPF were used to derive the standardized incidence ratio because cases of “flock-worker’s lung” probably would have been relegated to this broader ILD subcategory had the apparently specific clinicopathologic picture and occupational association been overlooked.

Interstitial Lung Disease — Continued

compounds, and negligible concentrations of metals. Respirable dust, characterized by both phase contrast microscopy and scanning electron microscopy with energy dispersive x-ray analysis, consisted of particles with physical structure and chemical composition similar to those of bulk samples of the finish components; a substantial number of respirable-size fragments of nylon also were present.

Reported by: DG Kern, MD, KTH Durand, MHS, RS Crausman, MD, A Neyer, MD, C Kuhn III, MD, Brown Univ School of Medicine, Providence; RR Vanderslice, PhD, Rhode Island Dept of Health. MD Lougheed, MD, DE O'Donnell, MD, PW Munt, MD, Queens' Univ, Kingston, Ontario, Canada. Div of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC.

Editorial Note: The findings in this report document an excessive incidence at two North American nylon flock production/flocking plants of a chronic diffuse ILD. The clinical and pathologic features of "flock-worker's lung" lack characteristics typically associated with previously recognized forms of occupational ILD (including hypersensitivity pneumonitis; pneumoconioses like silicosis or asbestosis; and those cases of BOOP that have followed acute massive exposure to a toxic gas, fume, or vapor) and indicate the occurrence of a previously unrecognized occupational illness.

The cause of the illness described in this report remains unknown. Although investigators of the ILD outbreak in Canada postulated an etiologic role for mycotoxins (3), no mycotoxins were detected at that plant, and two new cases of ILD occurred there after interventions were introduced to minimize mold growth; in addition, mycotoxin exposure has not been shown to cause chronic diffuse ILD. The findings in this report indicate a potential role for nylon flock and its finish in causing illness. Although intact nylon flock fibers are not considered respirable (i.e., they are too large to reach the respiratory bronchioles and gas-exchange units of the lung), preliminary evidence suggests that respirable-size nylon fragments are generated in this industry. This finding may have important implications because nylon is a polyamide, as are the agents recently implicated (4) in outbreaks of fatal BOOP among textile-dye sprayers in Spain and Algeria (5,6); furthermore, the biopsy specimens from one case-patient in Rhode Island revealed BOOP, and the index case-patient who did not have a biopsy had clinical findings that strongly suggested BOOP. Although the limited toxicologic data available for nylon and the three-component finish suggest the possibility that these substances may have adverse pulmonary effects (7-9), their role, if any, in causing "flock-worker's lung" has not been determined.

The two clusters described in this report together constitute the largest unexplained continuing outbreak of nongranulomatous chronic diffuse ILD in adults under investigation by CDC. Aspects of the illnesses of particular concern are the frequently subtle clinical, pulmonary function, and radiographic abnormalities; the potential for rapid clinical progression; and the apparent lack of complete reversibility. Until the specific cause of the outbreak is identified and eliminated, employers should ensure that work practices, engineering controls, and respirators are used to reduce respiratory exposures within the industry. Medical screening and surveillance should be intensified, and removal from exposure through alternative work or other accommodation should be offered to affected employees. CDC has initiated a series of toxicologic studies and is considering additional epidemiologic investigation within the flocking industry. Information concerning additional cases of ILD among workers employed in this industry can be reported to CDC's Epidemiological Investigations Branch, Division of Respiratory Disease Studies, NIOSH, telephone (304) 285-5751.

*Interstitial Lung Disease — Continued**References*

1. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. *Am J Respir Crit Care Med* 1994;150:967–72.
2. Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. *Am J Surg Pathol* 1994;18:136–47.
3. Loughheed MD, Roos JO, Waddell WR, Munt PW. Desquamative interstitial pneumonitis and diffuse alveolar damage in textile workers: potential role of mycotoxins. *Chest* 1995;108:1196–200.
4. Clottens FL, Verbeken EK, Demedts M, Nemery B. Pulmonary toxicity of components of textile paint linked to the Ardystil syndrome: intratracheal administration in hamsters. *Occup Environ Med* 1997;54:376–87.
5. Moya C, Anto JM, Newman Taylor AJ, and the Collaborative Group for the Study of Toxicity in Textile Aerographic Factories. Outbreak of organising pneumonia in textile printing sprayers. *Lancet* 1994;344:498–502.
6. Ould-Kadi F, Mohammed-Brahim B, Fyad A, Lellou S, Nemery B. Outbreak of pulmonary disease in textile dye sprayers in Algeria [Letter]. *Lancet* 1994;344:962–3.
7. Pimentel JC, Avila R, Lourenco AG. Respiratory disease caused by synthetic fibres: a new occupational disease. *Thorax* 1975;30:204–19.
8. Rohrbach MS. Modulation of alveolar macrophage function by condensed tannin. *Am J Ind Med* 1994;25:97–9.
9. Hollander A, Heederik D, Kauffman H. Acute respiratory effects in the potato processing industry due to a bioaerosol exposure. *Occup Environ Med* 1994;51:73–8.

*Notice to Readers***National Fire Prevention Week — October 5–11, 1997**

October 5–11 is National Fire Prevention Week. In the United States, a national health objective for 2000 is to reduce residential fire-related deaths to no more than 1.2 per 100,000 persons (objective 9.6) (1). In 1995, the United States had the highest death rate from fires of all developed countries (1.7 per 100,000 persons). During 1995 (the most recent year for which data are available), residential fires accounted for 3640 deaths and 18,650 injuries (2; CDC, unpublished data, 1995). Persons at highest risk were less likely to reside in homes equipped with functional smoke detector units (e.g., residents of manufactured homes and rental properties, low income and elderly persons, and children aged <5 years).

Most residential fires are caused by cooking or heating equipment, spontaneous combustion, or conditions suggesting arson. However, residential fires in which a death occurs are often caused by smoking, heating equipment, or conditions suggesting arson. Rates for fire-related death are highest in southern states, where use of wood-burning stoves and portable space heaters is widespread. In addition, these devices often are improperly placed and/or left unattended.

Although equipping homes with smoke detectors and adhering to basic fire-safety practices are the best deterrents to residential fires, many persons do not take these precautions. In 1995, an estimated 93% of U.S. homes were equipped with a smoke detector, but only 74% of homes had a smoke detector unit that was functional (3,4). The annual number of residential fire-related deaths could be reduced if all homes were equipped with sufficient functional smoke detector units.

Notice to Readers — Continued

Deaths and injuries from residential fires can be prevented by 1) installing a smoke detector on each habitable floor and one outside each bedroom; 2) replacing batteries in smoke detectors at least once a year; 3) designing and practicing a fire escape plan to ensure that exit from the home is quick and safe; 4) limiting use of heating devices (e.g., space heaters and wood-burning stoves) and, if using a heating device, carefully following manufacturer's operating guidelines; 5) keeping matches and lighters out of children's reach; and 6) not smoking.

Additional information about residential fire prevention is available from CDC's Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, telephone (770) 488-4652.

References

1. Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives—full report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service, 1991; DHHS publication no. (PHS)91-50212.
2. Karter MJ Jr. Fire loss in the United States during 1995. Quincy, Massachusetts: National Fire Protection Association, 1996.
3. Hall JR. U.S. experience with smoke detectors. Quincy, Massachusetts: National Fire Protection Association, 1996.
4. Smith CL. Smoke Detector Operability Survey: report on findings. Bethesda, Maryland: US Consumer Products Safety Commission, National Smoke Detector Project, 1994.


AIDS Rates

The following map provides the annual rates of acquired immunodeficiency syndrome (AIDS) per 100,000 population, by state of residence from July 1996 through June 1997. The accompanying table lists the metropolitan areas with the 50 highest annual rates of AIDS per 100,000 population.

More detailed information about AIDS cases is provided in the *HIV/AIDS Surveillance Report*, single copies of which are available from the CDC National AIDS Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003; telephone (800) 458-5231 or (301) 217-0023. Internet users can view an electronic copy of the report by accessing CDC's World-Wide Web home page (<http://www.cdc.gov>), then selecting "Publications, Software, & Products."

Rates presented here represent cases reported to CDC over the indicated 12-month period. Reported cases over a recent time period indicate the size and characteristics of the populations affected by the epidemic and the distribution and impact of AIDS nationally. These data are not appropriate for analyzing trends in the epidemic over time. Additional information about trends in the epidemic were published in *MMWR* 1997;46:861-7.

AIDS annual rates per 100,000 population — United States, July 1996–June 1997



*This rate represents only persons residing within the geographic boundaries of the District and differs from the rate for the larger Washington, D.C., metropolitan area (see table).


AIDS Rates — Continued

Metropolitan areas* with the 50 highest AIDS annual rates per 100,000 population — United States, July 1996–June 1997

Metropolitan area of residence	Rate	Metropolitan area of residence	Rate
New York, N.Y.	117.2	Tampa-Saint Petersburg, Fla.	29.8
Jersey City, N.J.	109.8	Dallas, Tex.	29.7
Miami, Fla.	86.6	Rochester, N.Y.	27.8
San Francisco, Calif.	83.1	Memphis, Tenn.	26.9
Newark, N.J.	80.0	Austin, Tex.	26.5
Fort Lauderdale, Fla.	78.4	Springfield, Mass.	26.5
West Palm Beach, Fla.	73.0	Richmond, Va.	26.3
San Juan, P.R.	70.2	Louisville, Ky.	25.0
Baltimore, Md.	61.8	Nassau-Suffolk, N.Y.	25.0
New Orleans, La.	48.7	Oakland, Calif.	24.8
Baton Rouge, La.	48.1	San Antonio, Tex.	24.8
Houston, Tex.	47.6	Syracuse, N.Y.	24.4
Washington, D.C.	44.2	Nashville, Tenn.	24.3
New Haven, Conn.	41.1	Middlesex, N.J.	23.9
Atlanta, Ga.	40.0	Monmouth-Ocean, N.J.	22.2
Bergen-Passaic, N.J.	39.7	Seattle, Wash.	22.2
Wilmington, Del.	39.2	Albany-Schenectady, N.Y.	22.0
Hartford, Conn.	37.1	Sarasota, Fla.	20.4
Jacksonville, Fla.	36.4	Fort Worth, Tex.	20.3
Los Angeles, Calif.	35.4	Albuquerque, N.M.	20.1
Orlando, Fla.	34.9	Chicago, Ill.	18.6
Buffalo, N.Y.	32.8	Riverside-San Bernardino, Calif.	18.6
Philadelphia, Pa.	32.1	Tucson, Ariz.	18.4
Norfolk, Va.	31.9	Denver, Colo.	17.5
Las Vegas, Nev.	31.8	Little Rock, Ark.	17.5
San Diego, Calif.	30.5		

* Includes only metropolitan areas with a population $\geq 500,000$. Metropolitan areas are named for a central city or county, may include several cities and counties, and may cross state boundaries.

FIGURE I. Selected notifiable disease reports, comparison of provisional 4-week totals ending September 20, 1997, with historical data — United States



*Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary — provisional cases of selected notifiable diseases, United States, cumulative, week ending September 20, 1997 (38th Week)

	Cum. 1997		Cum. 1997
Anthrax	-	Plague	2
Brucellosis	51	Poliomyelitis, paralytic	-
Cholera	6	Psittacosis	34
Congenital rubella syndrome	4	Rabies, human	2
Cryptosporidiosis*	1,151	Rocky Mountain spotted fever (RMSF)	293
Diphtheria	5	Streptococcal disease, invasive Group A	1,077
Encephalitis: California*	65	Streptococcal toxic-shock syndrome*	26
eastern equine*	4	Syphilis, congenital [†]	354
St. Louis*	2	Tetanus	30
western equine*	1	Toxic-shock syndrome	89
Hansen Disease	76	Trichinosis	7
Hantavirus pulmonary syndrome* [‡]	15	Typhoid fever	229
Hemolytic uremic syndrome, post-diarrheal*	42	Yellow fever	-
HIV infection, pediatric* [§]	173		

-:no reported cases

*Not notifiable in all states.

[†]Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID).

[‡]Updated monthly to the Division of HIV/AIDS Prevention—Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP), last update August 26, 1997.

[§]Updated from reports to the Division of STD Prevention, NCHSTP.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending September 20, 1997, and September 21, 1996 (38th Week)

Reporting Area	AIDS		Chlamydia		<i>Escherichia coli</i> O157:H7		Gonorrhea		Hepatitis C/NA,NB	
	Cum. 1997*	Cum. 1996	Cum. 1997	Cum. 1996	NETSS†	PHLIS‡	Cum. 1997	Cum. 1996	Cum. 1997	Cum. 1996
					Cum. 1997	Cum. 1997				
UNITED STATES	39,488	49,162	315,167	309,921	1,636	1,041	198,331	228,176	2,279	2,534
NEW ENGLAND	1,740	1,980	12,605	12,465	144	78	4,218	4,686	47	71
Maine	42	32	701	674	15	-	41	45	-	-
N.H.	26	66	554	535	8	12	72	121	8	7
Vt.	30	14	293	279	7	2	39	42	2	18
Mass.	604	995	5,220	4,943	76	58	1,567	1,582	30	40
R.I.	113	128	1,443	1,423	7	-	330	381	7	6
Conn.	925	745	4,394	4,611	31	6	2,169	2,515	-	-
MID. ATLANTIC	12,364	13,742	44,044	45,099	97	34	26,691	29,978	249	204
Upstate N.Y.	1,935	1,805	N	N	67	-	4,280	5,349	186	161
N.Y. City	6,469	7,840	22,538	22,890	8	6	10,145	10,688	-	3
N.J.	2,526	2,508	6,568	9,075	22	16	5,096	6,428	-	-
Pa.	1,434	1,589	14,938	13,134	N	12	7,170	7,513	63	40
E.N. CENTRAL	2,905	3,977	42,237	62,289	311	193	27,027	42,526	400	356
Ohio	626	835	8,256	15,095	75	38	5,728	10,949	14	26
Ind.	411	463	6,661	6,755	54	31	4,408	4,491	10	8
Ill.	1,186	1,799	7,714	17,801	56	-	3,763	12,616	65	71
Mich.	499	682	13,150	14,848	126	87	10,293	10,903	311	251
Wis.	183	198	6,456	7,790	N	37	2,835	3,567	-	-
W.N. CENTRAL	729	1,155	17,269	22,633	361	294	8,084	10,958	115	71
Minn.	138	188	U	3,560	155	151	U	1,610	3	1
Iowa	79	70	3,091	2,878	92	56	806	741	24	33
Mo.	318	619	8,448	9,194	37	47	5,328	6,203	74	18
N. Dak.	11	11	546	651	10	8	37	24	2	-
S. Dak.	7	10	865	1,068	24	24	94	134	-	-
Nebr.	72	74	1,658	2,036	27	-	657	770	2	6
Kans.	104	183	2,661	3,246	16	8	1,162	1,476	10	13
S. ATLANTIC	9,404	11,957	66,080	35,725	154	113	64,726	67,476	209	141
Del.	175	230	1,276	1,148	4	4	876	1,066	-	1
Md.	1,167	1,564	5,228	U	16	6	9,516	8,042	11	2
D.C.	657	871	N	N	2	-	3,187	3,209	-	-
Va.	769	800	8,426	8,067	N	38	5,922	6,789	22	12
W. Va.	79	87	2,138	1,559	N	1	682	558	13	9
N.C.	598	606	13,425	U	51	30	13,148	13,396	40	36
S.C.	545	625	9,152	U	8	7	8,464	8,275	32	21
Ga.	1,156	1,642	9,270	8,109	34	-	10,566	13,317	U	-
Fla.	4,258	5,532	17,165	16,842	38	27	12,365	12,824	91	60
E.S. CENTRAL	1,370	1,662	23,970	22,234	74	32	23,924	23,669	254	428
Ky.	234	307	4,680	4,868	23	-	2,974	3,036	11	27
Tenn.	576	605	9,232	9,685	37	32	7,904	8,558	180	319
Ala.	333	469	6,102	6,127	11	-	8,549	9,770	7	3
Miss.	227	281	3,956	1,554	3	-	4,497	2,305	56	79
W.S. CENTRAL	4,187	5,024	40,869	38,750	56	11	26,374	27,138	332	283
Ark.	160	205	965	1,317	9	1	2,068	3,013	2	8
La.	716	1,077	6,833	5,352	6	3	6,506	5,623	161	158
Okla.	215	191	5,490	5,551	7	4	3,616	3,553	7	1
Tex.	3,096	3,551	27,581	26,530	34	3	14,184	14,949	162	116
MOUNTAIN	1,114	1,416	17,138	18,649	195	102	5,764	5,656	327	436
Mont.	33	33	745	909	21	-	34	24	19	13
Idaho	37	31	1,043	1,130	24	13	83	81	43	92
Wyo.	13	5	427	449	15	-	42	32	150	136
Colo.	278	404	1,896	1,889	71	51	1,383	1,138	27	43
N. Mex.	112	116	2,359	2,874	7	5	945	606	48	63
Ariz.	273	373	7,723	8,082	N	23	2,574	2,789	24	52
Utah	88	142	1,184	1,148	47	-	186	227	3	19
Nev.	280	312	1,761	2,168	10	10	517	759	13	18
PACIFIC	5,675	8,248	50,955	52,077	244	184	11,523	16,089	346	544
Wash.	457	538	6,555	6,996	65	54	1,402	1,523	21	43
Oreg.	222	338	3,526	4,048	61	67	539	632	3	6
Calif.	4,918	7,208	38,626	38,907	107	56	8,958	13,291	207	342
Alaska	36	23	1,087	874	11	1	280	315	-	3
Hawaii	42	141	1,161	1,252	N	6	344	328	115	150
Guam	2	4	31	274	N	-	3	46	-	6
P.R.	1,382	1,511	U	U	32	U	441	493	96	127
V.I.	75	17	N	N	N	U	-	-	-	-
Amer. Samoa	-	-	-	-	N	U	-	-	-	-
C.N.M.I.	1	-	N	N	N	U	17	11	2	-

N: Not notifiable U: Unavailable -: no reported cases C.N.M.I.: Commonwealth of Northern Mariana Islands

*Updated monthly to the Division of HIV/AIDS Prevention—Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention, last update August 26, 1997.

†National Electronic Telecommunications System for Surveillance.

‡Public Health Laboratory Information System.

TABLE II. (Cont'd.) Provisional cases of selected notifiable diseases, United States, weeks ending September 20, 1997, and September 21, 1996 (38th Week)

Reporting Area	Legionellosis		Lyme Disease		Malaria		Syphilis (Primary & Secondary)		Tuberculosis		Rabies, Animal
	Cum. 1997	Cum. 1996	Cum. 1997	Cum. 1996	Cum. 1997	Cum. 1996	Cum. 1997	Cum. 1996	Cum. 1997	Cum. 1996	Cum. 1997
UNITED STATES	636	666	6,846	10,935	1,240	1,163	5,709	8,556	12,471	13,787	5,663
NEW ENGLAND	53	39	2,235	3,231	68	43	109	125	313	307	871
Maine	2	2	8	32	1	7	-	-	11	17	156
N.H.	6	3	24	40	7	2	-	1	10	9	28
Vt.	10	4	6	20	2	3	-	-	4	1	99
Mass.	16	21	235	171	24	15	53	60	179	149	188
R.I.	5	9	314	405	5	6	2	1	29	27	26
Conn.	14	N	1,648	2,563	29	10	54	63	80	104	374
MID. ATLANTIC	125	167	3,663	6,448	306	359	281	374	2,290	2,544	1,157
Upstate N.Y.	38	54	1,532	2,988	49	64	24	52	311	297	882
N.Y. City	6	11	43	313	170	219	64	109	1,171	1,333	U
N.J.	15	12	911	1,464	68	54	110	128	466	530	127
Pa.	66	90	1,177	1,683	19	22	83	85	342	384	148
E.N. CENTRAL	188	209	68	356	102	143	480	1,268	1,175	1,481	133
Ohio	84	71	46	19	16	13	145	476	222	211	89
Ind.	35	41	18	22	12	14	112	159	102	132	10
Ill.	7	30	4	8	31	71	48	360	561	791	12
Mich.	52	34	-	6	33	31	102	133	200	274	21
Wis.	10	33	U	301	10	14	73	140	90	73	1
W.N. CENTRAL	47	37	84	125	44	35	115	263	392	343	369
Minn.	1	3	56	38	19	15	U	31	104	80	41
Iowa	11	8	6	16	9	2	6	17	45	44	125
Mo.	15	10	16	39	7	9	82	185	164	144	16
N. Dak.	2	-	-	-	3	1	-	-	9	6	57
S. Dak.	2	2	1	-	1	-	-	-	9	15	60
Nebr.	12	11	2	3	1	2	5	10	14	14	1
Kans.	4	3	3	29	4	6	22	20	47	40	69
S. ATLANTIC	93	85	507	544	267	201	2,406	2,795	2,461	2,570	2,289
Del.	9	10	31	160	5	3	17	33	18	31	47
Md.	17	19	357	254	74	61	692	506	237	209	412
D.C.	4	7	7	3	14	7	82	101	75	102	5
Va.	19	13	45	40	59	33	175	304	220	201	477
W. Va.	N	N	5	11	-	3	3	9	45	45	69
N.C.	11	7	25	58	14	21	534	755	317	357	687
S.C.	5	4	2	4	15	9	280	298	229	268	144
Ga.	-	3	1	1	28	23	393	505	457	458	234
Fla.	27	22	34	13	58	41	230	284	863	899	214
E.S. CENTRAL	37	37	59	61	25	28	1,289	1,852	910	1,012	219
Ky.	6	5	7	22	5	7	104	102	124	173	27
Tenn.	25	17	34	17	7	12	567	617	321	341	122
Ala.	2	3	6	6	10	3	342	414	309	320	70
Miss.	4	12	12	16	3	6	276	719	156	178	-
W.S. CENTRAL	13	18	60	86	16	26	687	1,334	1,720	1,598	250
Ark.	-	1	16	20	4	-	71	191	140	139	27
La.	2	1	2	1	9	6	266	394	160	15	4
Okla.	3	6	12	14	3	-	89	142	132	123	84
Tex.	8	10	30	51	-	20	261	607	1,288	1,321	135
MOUNTAIN	43	34	15	7	59	48	165	107	353	447	148
Mont.	1	1	-	-	2	6	-	-	7	14	36
Idaho	2	-	3	-	-	-	1	4	8	7	-
Wyo.	1	3	3	3	2	7	-	2	2	6	30
Colo.	15	7	4	-	26	19	11	24	64	54	20
N. Mex.	2	1	1	1	8	2	46	4	21	63	9
Ariz.	9	15	1	-	9	6	93	58	180	172	41
Utah	8	2	1	1	3	4	5	2	25	39	5
Nev.	5	5	2	2	9	4	9	13	46	92	7
PACIFIC	37	40	155	77	353	280	177	438	2,857	3,485	227
Wash.	6	5	7	13	18	18	8	8	215	201	-
Oreg.	-	-	17	16	17	18	6	6	118	127	14
Calif.	30	31	131	47	313	234	161	422	2,338	2,958	190
Alaska	-	1	-	-	3	3	1	-	61	59	23
Hawaii	1	3	-	1	2	7	1	2	125	140	-
Guam	-	1	-	-	-	-	-	3	5	55	-
P.R.	-	-	-	-	5	1	183	163	164	130	54
V.I.	-	-	-	-	-	-	-	-	-	-	-
Amer. Samoa	-	-	-	-	-	-	-	-	-	-	-
C.N.M.I.	-	-	-	-	-	-	9	1	2	-	-

N: Not notifiable

U: Unavailable

-: no reported cases

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending September 20, 1997, and September 21, 1996 (38th Week)

Reporting Area	<i>H. influenzae</i> , invasive		Hepatitis (Viral), by type				Measles (Rubeola)					
	Cum. 1997*	Cum. 1996	A		B		Indigenous		Imported†		Total	
			Cum. 1997	Cum. 1996	Cum. 1997	Cum. 1996	1997	Cum. 1997	1997	Cum. 1997	Cum. 1997	Cum. 1996
UNITED STATES	766	786	20,106	20,095	6,141	7,002	1	60	-	47	107	445
NEW ENGLAND	45	26	474	274	108	159	-	11	-	6	17	15
Maine	5	-	47	15	6	2	-	-	-	1	1	-
N.H.	5	10	22	11	10	11	-	1	-	-	1	-
Vt.	3	1	10	6	5	11	-	-	-	-	-	2
Mass.	28	13	186	140	43	58	-	10	-	4	14	12
R.I.	2	2	111	13	12	9	-	-	-	-	-	-
Conn.	2	-	98	89	32	68	-	-	-	1	1	1
MID. ATLANTIC	95	163	1,367	1,404	915	1,052	-	14	-	8	22	36
Upstate N.Y.	23	40	233	318	202	253	-	2	-	3	5	10
N.Y. City	25	43	506	430	332	374	-	5	-	2	7	11
N.J.	37	44	193	276	155	203	-	2	-	-	2	3
Pa.	10	36	435	380	226	222	-	5	-	3	8	12
E.N. CENTRAL	128	133	1,962	1,858	650	811	-	6	-	3	9	20
Ohio	74	77	245	589	60	98	-	-	-	-	-	5
Ind.	13	8	220	244	74	104	-	-	-	-	-	-
Ill.	28	35	466	544	164	259	-	6	-	1	7	3
Mich.	12	8	917	321	320	280	-	-	-	2	2	3
Wis.	1	5	114	160	32	70	-	-	-	-	-	9
W.N. CENTRAL	41	36	1,605	1,723	330	365	1	12	-	5	17	22
Minn.	27	23	132	95	28	41	1	3	-	5	8	18
Iowa	6	3	343	265	30	53	-	-	-	-	-	-
Mo.	4	7	811	869	232	212	-	1	-	-	1	3
N. Dak.	-	-	10	84	4	2	-	-	-	-	-	-
S. Dak.	2	1	18	41	1	5	-	8	-	-	8	-
Nebr.	1	1	77	111	12	27	-	-	-	-	-	-
Kans.	1	1	214	258	23	25	-	-	-	-	-	1
S. ATLANTIC	130	145	1,312	873	934	954	-	1	-	10	11	11
Del.	-	2	24	13	5	7	-	-	-	-	-	1
Md.	47	52	174	149	130	121	-	-	-	2	2	2
D.C.	-	5	17	28	25	28	-	-	-	1	1	-
Va.	12	7	167	124	91	104	-	-	-	1	1	3
W. Va.	3	7	10	13	14	20	-	-	-	-	-	-
N.C.	19	22	150	106	180	266	-	-	-	2	2	2
S.C.	4	4	83	43	81	64	-	-	-	1	1	-
Ga.	25	31	274	89	105	10	-	-	-	1	1	2
Fla.	20	15	413	308	303	334	-	1	-	2	3	1
E.S. CENTRAL	38	23	461	1,009	493	620	-	-	-	-	-	2
Ky.	5	5	62	39	27	56	-	-	-	-	-	-
Tenn.	24	9	289	659	331	354	-	-	-	-	-	2
Ala.	9	8	69	145	55	50	-	-	-	-	-	-
Miss.	-	1	41	166	80	160	-	-	-	-	-	-
W.S. CENTRAL	38	32	4,255	3,944	735	858	-	3	-	4	7	25
Ark.	1	-	198	337	43	62	-	-	-	-	-	-
La.	10	3	169	125	113	92	-	-	-	-	-	-
Okla.	24	25	1,179	1,698	37	24	-	-	-	-	-	-
Tex.	3	4	2,709	1,784	542	680	-	3	-	4	7	25
MOUNTAIN	78	39	3,313	3,225	681	842	-	6	-	2	8	156
Mont.	-	-	59	91	7	10	-	-	-	-	-	-
Idaho	1	1	101	165	27	74	-	-	-	-	-	1
Wyo.	3	-	30	26	30	35	-	-	-	-	-	1
Colo.	12	11	319	334	124	101	-	-	-	-	-	7
N. Mex.	8	9	270	304	203	302	-	-	-	-	-	16
Ariz.	29	12	1,731	1,253	154	186	-	5	-	-	5	8
Utah	3	6	474	748	76	73	-	-	-	1	1	118
Nev.	22	-	329	304	60	61	-	1	-	1	2	5
PACIFIC	173	189	5,357	5,785	1,295	1,341	-	7	-	9	16	158
Wash.	4	2	416	357	54	72	-	1	-	1	2	38
Oreg.	29	25	276	678	76	81	-	-	-	-	-	12
Calif.	128	155	4,537	4,654	1,140	1,168	-	4	-	7	11	38
Alaska	5	5	25	36	17	9	-	-	-	-	-	63
Hawaii	7	2	103	60	8	11	-	2	-	1	3	7
Guam	-	-	-	7	1	1	U	-	U	-	-	-
P.R.	-	1	223	161	1,077	697	-	-	-	-	-	2
V.I.	-	-	-	30	-	28	U	-	U	-	-	-
Amer. Samoa	-	-	-	-	-	-	U	-	U	-	-	-
C.N.M.I.	6	10	1	1	34	5	U	1	U	-	1	-

N: Not notifiable U: Unavailable -: no reported cases

*Of 174 cases among children aged <5 years, serotype was reported for 93 and of those, 38 were type b.

†For imported measles, cases include only those resulting from importation from other countries.

TABLE III. (Cont'd.) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending September 20, 1997, and September 21, 1996 (38th Week)

Reporting Area	Meningococcal Disease		Mumps			Pertussis			Rubella		
	Cum. 1997	Cum. 1996	1997	Cum. 1997	Cum. 1996	1997	Cum. 1997	Cum. 1996	1997	Cum. 1997	Cum. 1996
UNITED STATES	2,417	2,364	8	416	521	90	3,640	4,034	1	137	214
NEW ENGLAND	154	98	-	8	1	14	664	853	-	1	25
Maine	17	10	-	-	-	-	6	32	-	-	-
N.H.	13	3	-	-	-	1	81	72	-	-	-
Vt.	4	3	-	-	-	1	191	74	-	-	2
Mass.	74	40	-	2	1	10	355	624	-	1	20
R.I.	14	10	-	5	-	-	12	25	-	-	-
Conn.	32	32	-	1	-	2	19	26	-	-	3
MID. ATLANTIC	216	250	1	43	63	7	273	303	-	29	10
Upstate N.Y.	54	66	-	7	19	-	94	160	-	2	4
N.Y. City	39	37	-	3	16	-	56	28	-	27	4
N.J.	46	53	-	5	2	-	9	21	-	-	2
Pa.	77	94	1	28	26	7	114	94	-	-	-
E.N. CENTRAL	340	343	-	44	105	1	302	507	-	5	3
Ohio	134	124	-	19	39	-	109	191	-	-	-
Ind.	41	50	-	7	6	-	39	36	-	-	-
Ill.	100	94	-	9	19	1	55	119	-	2	1
Mich.	39	35	-	9	39	-	40	32	-	-	2
Wis.	26	40	-	-	2	-	59	129	-	3	-
W.N. CENTRAL	178	191	-	14	15	19	304	247	-	-	-
Minn.	29	25	-	5	5	12	196	186	-	-	-
Iowa	39	40	-	7	1	3	33	13	-	-	-
Mo.	78	72	-	-	6	4	50	27	-	-	-
N. Dak.	2	3	-	-	2	-	2	1	-	-	-
S. Dak.	5	10	-	-	-	-	4	4	-	-	-
Nebr.	8	18	-	2	-	-	6	5	-	-	-
Kans.	17	23	-	-	1	-	13	11	-	-	-
S. ATLANTIC	432	371	5	61	87	27	363	422	1	69	91
Del.	5	2	-	-	-	-	1	19	-	-	-
Md.	40	44	-	4	28	1	102	154	-	3	-
D.C.	-	5	-	-	-	-	3	-	-	1	1
Va.	40	44	1	10	12	8	42	56	-	1	2
W. Va.	14	13	1	1	-	-	6	2	-	-	-
N.C.	78	62	-	9	19	10	99	76	1	53	77
S.C.	45	45	-	10	5	2	22	26	-	9	1
Ga.	83	110	-	8	3	-	11	19	-	-	-
Fla.	127	46	3	19	20	6	77	70	-	2	10
E.S. CENTRAL	189	168	1	21	19	2	82	178	-	-	2
Ky.	38	21	-	3	-	-	21	135	-	-	-
Tenn.	72	48	1	5	1	1	32	18	-	-	-
Ala.	62	59	-	7	3	1	21	18	-	-	2
Miss.	17	40	-	6	15	-	8	7	-	-	N
W.S. CENTRAL	236	266	1	45	38	9	164	106	-	4	8
Ark.	29	29	-	1	1	2	28	4	-	-	-
La.	46	49	-	12	12	2	17	7	-	-	1
Okla.	30	29	-	-	-	3	25	8	-	-	-
Tex.	131	159	1	32	25	2	94	87	-	4	7
MOUNTAIN	147	140	-	51	21	5	897	364	-	6	6
Mont.	8	6	-	-	-	-	16	26	-	-	-
Idaho	8	20	-	2	-	-	542	100	-	1	2
Wyo.	2	3	-	1	-	1	7	4	-	-	-
Colo.	38	29	-	3	3	2	199	122	-	-	2
N. Mex.	23	22	N	N	N	2	74	46	-	-	-
Ariz.	41	32	-	31	1	-	31	24	-	5	1
Utah	12	12	-	7	3	-	14	13	-	-	-
Nev.	15	16	-	7	14	-	14	29	-	-	1
PACIFIC	525	537	-	129	172	6	591	1,054	-	23	69
Wash.	63	75	-	14	18	6	267	456	-	5	15
Oreg.	102	95	N	N	N	-	17	51	-	-	1
Calif.	353	357	-	95	127	-	282	519	-	10	50
Alaska	2	6	-	3	2	-	14	2	-	-	-
Hawaii	5	4	-	17	25	-	11	26	-	8	3
Guam	-	4	U	1	6	U	-	-	U	-	-
P.R.	9	11	-	7	1	-	-	2	-	-	-
V.I.	-	-	U	-	1	U	-	-	U	-	-
Amer. Samoa	-	-	U	-	-	U	-	-	U	-	-
C.N.M.I.	-	-	U	4	-	U	-	-	U	-	-

N: Not notifiable

U: Unavailable

-: no reported cases

**TABLE IV. Deaths in 122 U.S. cities,* week ending
September 20, 1997 (38th Week)**

Reporting Area	All Causes, By Age (Years)						P&J† Total	Reporting Area	All Causes, By Age (Years)						P&J† Total
	All Ages	>65	45-64	25-44	1-24	<1			All Ages	>65	45-64	25-44	1-24	<1	
NEW ENGLAND	550	393	92	41	17	7	44	S. ATLANTIC	1,268	805	255	127	43	36	54
Boston, Mass.	150	101	26	14	8	1	12	Atlanta, Ga.	155	94	33	20	4	4	2
Bridgeport, Conn.	37	32	3	1	1	-	3	Baltimore, Md.	189	113	39	24	5	6	13
Cambridge, Mass.	24	21	3	-	-	-	2	Charlotte, N.C.	88	58	15	9	3	3	3
Fall River, Mass.	34	30	3	1	-	-	3	Jacksonville, Fla.	137	91	27	13	4	2	3
Hartford, Conn.	59	34	14	8	1	2	2	Miami, Fla.	107	64	29	8	4	2	3
Lowell, Mass.	17	15	1	-	1	-	3	Norfolk, Va.	51	31	7	2	6	5	-
Lynn, Mass.	16	13	-	2	1	-	2	Richmond, Va.	95	50	20	20	3	2	6
New Bedford, Mass.	21	17	2	2	-	-	2	Savannah, Ga.	54	32	16	3	1	2	3
New Haven, Conn.	40	24	10	2	2	2	3	St. Petersburg, Fla.	58	49	1	6	-	2	1
Providence, R.I.	47	36	5	5	1	-	-	Tampa, Fla.	183	146	20	10	4	3	18
Somerville, Mass.	5	4	-	1	-	-	-	Washington, D.C.	130	66	38	12	9	5	2
Springfield, Mass.	41	25	11	3	1	1	5	Wilmington, Del.	21	11	10	-	-	-	-
Waterbury, Conn.	18	13	4	-	1	-	2	E.S. CENTRAL	820	545	164	71	17	21	56
Worcester, Mass.	41	28	10	2	-	1	5	Birmingham, Ala.	174	129	24	16	1	2	20
MID. ATLANTIC	2,192	1,508	428	175	46	35	109	Chattanooga, Tenn.	56	43	7	4	1	1	3
Albany, N.Y.	44	32	7	3	1	1	5	Knoxville, Tenn.	107	67	27	7	-	6	4
Allentown, Pa.	14	12	2	-	-	-	1	Lexington, Ky.	71	48	11	8	3	1	11
Buffalo, N.Y.	59	41	14	1	1	2	2	Memphis, Tenn.	227	136	58	20	6	7	16
Camden, N.J.	34	17	8	6	2	1	3	Mobile, Ala.	18	11	3	3	1	-	-
Elizabeth, N.J.	18	13	3	2	-	-	-	Montgomery, Ala.	24	19	4	1	-	-	2
Erie, Pa.	43	36	3	3	1	-	2	Nashville, Tenn.	143	92	30	12	5	4	-
Jersey City, N.J.	27	21	3	3	-	-	1	W.S. CENTRAL	1,384	836	324	137	47	38	63
New York City, N.Y.	1,131	765	234	87	20	25	46	Austin, Tex.	71	40	16	9	5	1	1
Newark, N.J.	58	22	22	9	5	-	6	Baton Rouge, La.	41	28	9	2	-	2	2
Paterson, N.J.	37	25	8	4	-	-	-	Corpus Christi, Tex.	50	34	11	5	-	-	4
Philadelphia, Pa.	300	199	61	30	7	3	12	Dallas, Tex.	177	98	37	25	10	7	3
Pittsburgh, Pa.‡	60	47	9	4	-	-	5	El Paso, Tex.	63	43	14	4	1	1	5
Reading, Pa.	33	29	2	2	-	-	1	Ft. Worth, Tex.	96	56	18	13	5	4	2
Rochester, N.Y.	121	88	22	5	5	1	10	Houston, Tex.	374	209	115	33	8	9	25
Schenectady, N.Y.	14	13	1	-	-	-	1	Little Rock, Ark.	74	48	17	4	4	1	2
Scranton, Pa.	28	22	4	2	-	-	2	New Orleans, La.	105	66	15	14	3	7	-
Syracuse, N.Y.	78	57	13	5	2	1	6	San Antonio, Tex.	186	114	47	17	3	3	11
Trenton, N.J.	52	34	9	6	2	1	5	Shreveport, La.	63	40	12	4	5	2	6
Utica, N.Y.	14	11	1	2	-	-	-	Tulsa, Okla.	84	60	13	7	3	1	2
Yonkers, N.Y.	27	24	2	1	-	-	1	MOUNTAIN	872	556	166	97	30	18	51
E.N. CENTRAL	1,971	1,325	390	163	43	49	103	Albuquerque, N.M.	63	42	10	7	2	2	-
Akron, Ohio	45	33	8	1	1	2	1	Boise, Idaho	31	21	7	1	-	1	2
Canton, Ohio	42	35	5	-	-	-	6	Colo. Springs, Colo.	48	34	8	3	-	3	3
Chicago, Ill.	397	237	94	46	9	10	22	Denver, Colo.	89	50	22	15	1	1	8
Cincinnati, Ohio	89	62	14	4	4	5	7	Las Vegas, Nev.	195	113	53	22	5	1	12
Cleveland, Ohio	134	78	32	16	3	5	3	Ogden, Utah	23	18	-	4	1	-	3
Columbus, Ohio	230	152	49	21	5	3	14	Phoenix, Ariz.	154	98	23	20	10	3	7
Dayton, Ohio	107	74	21	9	3	-	6	Pueblo, Colo.	27	19	5	2	1	-	2
Detroit, Mich.	209	113	57	26	6	7	-	Salt Lake City, Utah	101	63	18	9	5	3	7
Evansville, Ind.	34	25	7	1	1	-	2	Tucson, Ariz.	141	98	20	14	5	4	7
Fort Wayne, Ind.	56	44	7	2	3	-	8	PACIFIC	2,032	1,425	376	133	60	38	153
Gary, Ind.	U	U	U	U	U	U	U	Berkeley, Calif.	14	9	5	-	-	-	1
Grand Rapids, Mich.	55	42	9	1	3	-	2	Fresno, Calif.	41	30	7	2	2	-	4
Indianapolis, Ind.	162	120	24	9	2	7	8	Glendale, Calif.	33	25	6	1	-	1	1
Lansing, Mich.	30	23	3	3	-	1	3	Honolulu, Hawaii	78	56	13	4	3	2	3
Milwaukee, Wis.	116	85	17	12	-	2	7	Long Beach, Calif.	86	50	26	6	3	1	12
Peoria, Ill.	27	17	6	2	1	1	2	Los Angeles, Calif.	649	466	109	39	23	12	30
Rockford, Ill.	54	43	4	3	2	2	2	Pasadena, Calif.	40	28	7	1	1	3	5
South Bend, Ind.	33	24	7	2	-	-	-	Portland, Oreg.	198	131	31	23	12	1	4
Toledo, Ohio	104	79	20	4	-	1	8	Sacramento, Calif.	198	150	31	11	3	3	34
Youngstown, Ohio	47	39	6	1	-	1	2	San Diego, Calif.	122	75	36	7	3	1	16
W.N. CENTRAL	745	536	120	48	22	9	43	San Francisco, Calif.	139	89	30	14	3	3	16
Des Moines, Iowa	U	U	U	U	U	U	U	San Jose, Calif.	165	123	30	7	3	2	14
Duluth, Minn.	34	25	6	2	1	-	1	Santa Cruz, Calif.	39	28	7	4	-	-	5
Kansas City, Kans.	33	21	5	3	3	1	-	Seattle, Wash.	126	84	22	10	2	8	1
Kansas City, Mo.	83	54	14	4	1	-	9	Spokane, Wash.	37	27	8	1	-	1	5
Lincoln, Nebr.	26	21	3	2	-	-	2	Tacoma, Wash.	67	54	8	3	2	-	2
Minneapolis, Minn.	240	183	35	11	9	2	13	TOTAL	11,834†	7,929	2,315	992	325	251	676
Omaha, Nebr.	85	57	14	10	2	2	6								
St. Louis, Mo.	112	80	18	8	4	2	7								
St. Paul, Minn.	53	38	10	4	-	1	2								
Wichita, Kans.	79	57	15	4	2	1	3								

U: Unavailable - : no reported cases

*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

†Pneumonia and influenza.

‡Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

††Total includes unknown ages.

Contributors to the Production of the *MMWR* (Weekly)

Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Denise Koo, M.D., M.P.H.

State Support Team

Robert Fagan
Karl A. Brendel
Siobhan Gilchrist, M.P.H.
Harry Holden
Gerald Jones
Felicia Perry
Carol A. Worsham

CDC Operations Team

Carol M. Knowles
Deborah A. Adams
Willie J. Anderson
Christine R. Burgess
Patsy A. Hall
Myra A. Montalbano
Angela Trosclair, M.S.

Desktop Publishing and Graphics Support

Morie M. Higgins
Peter M. Jenkins

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov/> or from CDC's file transfer protocol server at <ftp.cdc.gov>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention David Satcher, M.D., Ph.D.	Acting Editor, <i>MMWR</i> (weekly) John W. Ward, M.D.
Deputy Director, Centers for Disease Control and Prevention Claire V. Broome, M.D.	Managing Editor, <i>MMWR</i> (weekly) Karen L. Foster, M.A.
Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.	Writers-Editors, <i>MMWR</i> (weekly) David C. Johnson Darlene D. Rumph Person Teresa F. Rutledge
Editor, <i>MMWR</i> Series Richard A. Goodman, M.D., M.P.H.	Caran R. Wilbanks

☆ U.S. Government Printing Office: 1997-532-228/67028 Region IV
